Spero Therapeutics, Inc. (NASDAQ:SPRO) Short Interest Update

Spero Therapeutics, Inc. (NASDAQ:SPRO - Get Free Report) saw a significant drop in short interest in the month of April. As of April 15th, there was short interest totalling 513,200 shares, a drop of 21.5% from the March 31st total of 653,800 shares. Based on an average trading volume of 321,500 shares, the days-to-cover ratio is currently 1.6 days.

Spero Therapeutics Price Performance

Shares of NASDAQ:SPRO traded up $0.03 during midday trading on Friday, reaching $1.46. The company's stock had a trading volume of 165,357 shares, compared to its average volume of 219,213. Spero Therapeutics has a fifty-two week low of $0.99 and a fifty-two week high of $2.00. The company has a market capitalization of $78.68 million, a P/E ratio of 3.48 and a beta of 0.55. The business's fifty day simple moving average is $1.63 and its 200-day simple moving average is $1.42.

Spero Therapeutics (NASDAQ:SPRO - Get Free Report) last announced its earnings results on Wednesday, March 13th. The company reported $0.96 earnings per share for the quarter, beating analysts' consensus estimates of ($0.18) by $1.14. Spero Therapeutics had a return on equity of 38.54% and a net margin of 21.98%. The company had revenue of $73.52 million during the quarter, compared to analyst estimates of $19.40 million. On average, analysts forecast that Spero Therapeutics will post -0.94 earnings per share for the current fiscal year.

Institutional Trading of Spero Therapeutics

A hedge fund recently raised its stake in Spero Therapeutics stock. Acadian Asset Management LLC increased its position in Spero Therapeutics, Inc. (NASDAQ:SPRO - Free Report) by 56.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 272,024 shares of the company's stock after purchasing an additional 98,485 shares during the quarter. Acadian Asset Management LLC owned approximately 0.52% of Spero Therapeutics worth $327,000 as of its most recent SEC filing. 25.60% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on SPRO shares. Cantor Fitzgerald reissued an "overweight" rating on shares of Spero Therapeutics in a report on Thursday, April 4th. HC Wainwright reissued a "buy" rating and set a $7.00 price objective on shares of Spero Therapeutics in a report on Monday, March 18th.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.